Legal Representation
Attorney
Stewart J Bellus
USPTO Deadlines
Next Deadline
766 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2021-09-07)
Due Date
September 07, 2027
Grace Period Ends
March 07, 2028
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
31 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| May 7, 2024 | ADCH | M | CHANGE OF NAME/ADDRESS REC'D FROM IB | Loading... |
| May 27, 2023 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED | Loading... |
| May 14, 2023 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED | Loading... |
| Apr 1, 2022 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED | Loading... |
| Mar 7, 2022 | FINO | P | FINAL DECISION TRANSACTION PROCESSED BY IB | Loading... |
| Feb 15, 2022 | FICS | P | FINAL DISPOSITION NOTICE SENT TO IB | Loading... |
| Feb 14, 2022 | FIMP | P | FINAL DISPOSITION PROCESSED | Loading... |
| Dec 7, 2021 | FICR | P | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | Loading... |
| Oct 27, 2021 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED | Loading... |
| Sep 7, 2021 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Jul 17, 2021 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED | Loading... |
| Jun 22, 2021 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Jun 22, 2021 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Jun 2, 2021 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| May 18, 2021 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| May 18, 2021 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| May 18, 2021 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| May 18, 2021 | GNEA | O | EXAMINERS AMENDMENT E-MAILED | Loading... |
| May 18, 2021 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| May 17, 2021 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| May 17, 2021 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| May 17, 2021 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Apr 5, 2021 | RFNT | P | REFUSAL PROCESSED BY IB | Loading... |
| Mar 12, 2021 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | Loading... |
| Mar 12, 2021 | RFRR | P | REFUSAL PROCESSED BY MPU | Loading... |
| Mar 12, 2021 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | Loading... |
| Mar 11, 2021 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Mar 1, 2021 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Nov 3, 2020 | MAFR | O | APPLICATION FILING RECEIPT MAILED | Loading... |
| Oct 30, 2020 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Oct 29, 2020 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB | Loading... |
Detailed Classifications
Class 001
Chemical additives for the manufacture of cosmetics, nutraceuticals and foodstuffs
Class 003
Cosmetics
Class 005
Nutraceutical preparations for humans for treating irritable bowel syndrome symptoms (IBS), gut mobility diseases, food intolerance discomfort, skin diseases, chronic inflammaging, discomfort and constipation, constipation and bloating in infants and adults, nausea; Nutraceutical preparations as dietary supplements for humans with healthy effects in the balance of the intestinal flora, regularity of the intestinal transit, gastro-intestinal mucosal functionality, sleep quality, systemic inflammation preventing, joint functionality, metabolism of carbohydrates, metabolism of the cholesterol, immunity, fluidity of bronchial secretions, regularity of the menstrual cycle, drainage of liquids bodily, regularity of the process of sweating, noise contrast of menopause, regularity of blood pressure, regularity of arterial pressure, contrast of blemishes of cellulite, modulation and/or limitation of the absorption of nutrients, well-being of nails and hair, tropism and skin functionality; Dietetic foods adapted for medical use; Pharmaceutical preparations and substances for treating atopic dermatitis, dry eyes, ostheoarthritis; Chemical preparations for pharmaceutical use for treating atopic dermatitis, dry eyes, and ostheoarthritis
Additional Information
Design Mark
The mark consists of two blue and two light blue ovals that intersect at center focal point. The wording "SINO LIFESCIENCE" appears to the right of the ovals. From left to right, the wording begins blue and progresses to light blue. The white background is not claimed as a feature of the mark.
Color Claim
The color(s) blue and light blue is/are claimed as a feature of the mark.
Pseudo Mark
SINO LIFE SCIENCE
Classification
International Classes
001
003
005
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"SINO LIFE SCIENCE"